MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.67 (157.86% upside)

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2015BTIG ResearchInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2015Leerink SwannBoost Price TargetOutperform$10.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2015WedbushInitiated CoverageBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014Leerink SwannInitiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2013WedbushDowngradeOutperform -> Neutral$1.20View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2013OppenheimerDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/28/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha